Associations - PD-L1 underexpression

PD-L1 underexpression PD-L1 underexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	PD-L1 underexpression PD-L1 underexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	nivolumab + ipilimumab Sensitive: C1 - Off-label Thorac Cancer - 2 weeks	nivolumab + ipilimumab Sensitive: C1 - Off-label Thorac Cancer - 2 weeks
PD-L1 underexpression PD-L1 underexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	PD-L1 underexpression PD-L1 underexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: C3 – Early Trials Thorac Cancer - 2 weeks	pembrolizumab Sensitive: C3 – Early Trials Thorac Cancer - 2 weeks
PD-L1 underexpression PD-L1 underexpression	Melanoma Melanoma	PD-L1 underexpression PD-L1 underexpression	Melanoma Melanoma	ipilimumab Sensitive: A1 - Approval	ipilimumab Sensitive: A1 - Approval
PD-L1 underexpression PD-L1 underexpression	Melanoma Melanoma	PD-L1 underexpression PD-L1 underexpression	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
PD-L1 underexpression PD-L1 underexpression	Lung Adenocarcinoma LUAD	PD-L1 underexpression PD-L1 underexpression	Lung Adenocarcinoma LUAD	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	nivolumab Resistant: B - Late Trials	nivolumab Resistant: B - Late Trials
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	durvalumab + CP-675206 Sensitive: B - Late Trials	durvalumab + CP-675206 Sensitive: B - Late Trials
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: C2 – Inclusion Criteria	pembrolizumab Sensitive: C2 – Inclusion Criteria
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	camrelizumab Sensitive: C3 – Early Trials	camrelizumab Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	ipilimumab + cemiplimab Sensitive: C3 – Early Trials	ipilimumab + cemiplimab Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Urothelial Cancer Urothelial Cancer	PD-L1 underexpression PD-L1 underexpression	Urothelial Cancer Urothelial Cancer	nivolumab + IPI-549 Sensitive: C3 – Early Trials	nivolumab + IPI-549 Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Mantle Cell Lymphoma Mantle Cell Lymphoma	PD-L1 underexpression PD-L1 underexpression	Mantle Cell Lymphoma Mantle Cell Lymphoma	ibrutinib Resistant: C3 – Early Trials	ibrutinib Resistant: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Cutaneous T-cell Lymphoma Cutaneous T-cell Lymphoma	PD-L1 underexpression PD-L1 underexpression	Cutaneous T-cell Lymphoma Cutaneous T-cell Lymphoma	durvalumab + lenalidomide Sensitive: C3 – Early Trials	durvalumab + lenalidomide Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 underexpression PD-L1 underexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab + RG6180 Sensitive: C3 – Early Trials	atezolizumab + RG6180 Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Acute Myelogenous Leukemia AML	PD-L1 underexpression PD-L1 underexpression	Acute Myelogenous Leukemia AML	XmAb14045 Sensitive: C3 – Early Trials	XmAb14045 Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	PD-L1 underexpression PD-L1 underexpression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	PD1 inhibitor Resistant: C3 – Early Trials	PD1 inhibitor Resistant: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 underexpression PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab sarotalocan Sensitive: C3 – Early Trials	cetuximab sarotalocan Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	avelumab + VX15 Sensitive: C3 – Early Trials	avelumab + VX15 Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Gastric Adenocarcinoma Gastric Adenocarcinoma	PD-L1 underexpression PD-L1 underexpression	Gastric Adenocarcinoma Gastric Adenocarcinoma	toripalimab + surufatinib Sensitive: C3 – Early Trials	toripalimab + surufatinib Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	PD-L1 underexpression PD-L1 underexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	toripalimab + surufatinib Sensitive: C3 – Early Trials	toripalimab + surufatinib Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Colorectal Cancer CRC	PD-L1 underexpression PD-L1 underexpression	Colorectal Cancer CRC	atezolizumab + RG6180 Sensitive: C3 – Early Trials	atezolizumab + RG6180 Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Melanoma Melanoma	PD-L1 underexpression PD-L1 underexpression	Melanoma Melanoma	atezolizumab + RG6180 Sensitive: C3 – Early Trials	atezolizumab + RG6180 Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab + RG6180 Sensitive: C3 – Early Trials	atezolizumab + RG6180 Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: C3 – Early Trials	durvalumab Resistant: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Renal Cell Carcinoma RCC	PD-L1 underexpression PD-L1 underexpression	Renal Cell Carcinoma RCC	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Hepatocellular Cancer HCC	PD-L1 underexpression PD-L1 underexpression	Hepatocellular Cancer HCC	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials